Research Article
Volume 9 Issue 4 - 2021
Reduced Ex Vivo Sensitivity of Post Artemether-Lumefantrine Treatment Recurrent P. falciparum Isolates to Dihydroartemisinin and Piperaquine
Karim Traoré1*, Seidina AS Diakité1, Sekou Bah2, Drissa S Konaté1 and Mahamadou Diakité1
1Malaria Research and Training Center, Mali International Center for Excellence in Research (Mali-ICER), University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
2Hospital of Point-G/University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
*Corresponding Author: Karim Traoré, Malaria Research and Training Center, Mali International Center for Excellence in Research (Mali-ICER), University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali.
Received: September 17, 2020; Published: March 31, 2021




Abstract

Introduction: Since 2006, the Malian National Malaria Control Program (NMCP) adapted the Artemisinin based therapeutic combination (ATC) as the first line treatment molecule of uncomplicated malaria. Artemether + lumefantrine appears to be the most ACT used in Mali. However, recent studies reported increased recurrence of post AL treatment P. falciparum infections.

Methods: Using the SYBR® Green fluorometric method of IC50 determination, we compared the sensitivity ex vivo of post AL recurrent and non-recurrent P. falciparum isolates to common antimalarial molecules.

Results: Compared to non-recurrent, post AL treatment recurrent P. falciparum isolates harbored higher IC50’s values (geometric mean, number [Min-Max]) to dihydroartemisinin (0.87 nM, 68, [0.34 - 4 nM] vs 1.14 nM, 7, [0.34 - 6 nM]; P = 0.003) and piperaquine (15.8 nM, 74 [13 - 22.6 nM] vs 17.54 nM, 6 [4.5 - 40.2 nM]; P = 0.001). Recurrent and non-recurrent P. falciparum isolates showed similar IC50’s values with mefloquine (13.35 nM, 8 [1 - 28 nM] and 12.85 nM, 74 [4 - 36 nM]; P=0.29). The geometric mean IC50 to lumefantrine in recurrent isolates (14.52 nM, 8 [3 - 50.82 nM]) was higher than that of the non-recurrent isolates (9.9 nM, 71 [1 - 38.71 nM]) but the difference was not statistically significant (p = 0.53). The geometric mean IC50 to amodiaquine for recurrent isolates (24.75 nM, 73 [9 - 88 nM]) was higher than to non-recurrent isolates (22.92 nM, 6 [5 - 88 nM]), but the difference was not statistically significant (p = 0.09).

Conclusion: Our study revealed a lower sensitivity of Post AL treatment recurrent P. falciparum isolates to dihydroartemisinin and piperaquine and a trend to higher sensitivity of those parasite to amodiaquine.

Keywords: P. falciparum; Sensitivity; Recurrent; Antimalarial Drug; Ex vivo

References

  1. Organization WH. Guidelines for the treatment of malaria. WHO (2011).
  2. Pnlp, Directives Nationales Pour La Prise En Charge Des Cas De Paludisme Au Mali (2016).
  3. Ariey FWB., et al. “Un marqueur moléculaire du paludisme à Plasmodium falciparum résistant à l'artémisinine”. La nature 505 (2014): 50-55.
  4. Rapport mondial sur l'efficacité des médicaments antipaludiques et la pharmacorésistance: 2000-2010. Genève, S.O.m.d.l.s., Rapport mondial sur l'efficacité des médicaments antipaludiques et la pharmacorésistance: 2000-2010. Genève, Suisse: Organisation mondiale de la santé (2011).
  5. Phyo AP., et al. “Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study”. Lancet9830 (2012): 1960-1966.
  6. Amaratunga C., et al. “Artemisinin-resistant Plasmodium falciparum in Pursat province, western Cambodia: a parasite clearance rate study”. The Lancet Infectious Diseases 11 (2012): 851-858.
  7. Sagara I., et al. “A randomized trial of artesunate-mefloquine versus artemether-lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Mali”. The American Journal of Tropical Medicine and Hygiene 5 (2008): 655-661.
  8. Sagara I., et al. “A randomized trial of artesunate-sulfamethoxypyrazine-pyrimethamine versus artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Mali”. The American Journal of Tropical Medicine and Hygiene 4 (2006): 630-636.
  9. Dama S., et al. “Reduced ex vivo susceptibility of Plasmodium falciparum after oral artemether-lumefantrine treatment in Mali”. Malaria Journal 1 (2017): 59.
  10. Sisowath C., et al. “In vivo selection of Plasmodium falciparum parasites carrying the chloroquine-susceptible pfcrt K76 allele after treatment with artemether-lumefantrine in Africa”. The Journal of Infectious Diseases 5 (2009): 750-757.
  11. Holmgren G., et al. “Selection of pfmdr1 mutations after amodiaquine monotherapy and amodiaquine plus artemisinin combination therapy in East Africa”. Infection, Genetics and Evolution 5 (2007): 562-569.
  12. Dahlstrom S., et al. “Plasmodium falciparum multidrug resistance protein 1 and artemisinin-based combination therapy in Africa”. The Journal of Infectious Diseases 9 (2009): 1456-1464.
  13. Adjuik M., et al. “Artesunate combinations for treatment of malaria: meta-analysis”. Lancet9402 (2004): 9-17.
  14. Kokwaro G., et al. “Artemether/lumefantrine in the treatment of uncomplicated falciparum malaria”. Expert Opinion on Pharmacotherapy 1 (2007): 75-94.
  15. Targett G., et al. “Artesunate reduces but does not prevent posttreatment transmission of Plasmodium falciparum to Anopheles gambiae”. The Journal of Infectious Diseases 8 (2001): 1254-1259.
  16. Price RN., et al. “Effects of artemisinin derivatives on malaria transmissibility”. Lancet9016 (1996): 1654-1658.
  17. Smilkstein M., et al. “Simple and inexpensive fluorescence-based technique for high-throughput antimalarial drug screening”. Antimicrobial Agents and Chemotherapy 5 (2004): 1803-1806.
  18. Johnson DJ., et al. “Evidence for a central role for PfCRT in conferring Plasmodium falciparum resistance to diverse antimalarial agents”. Molecular Cell 6 (2004): 867-877.
  19. Le Nagard H., et al. “Online analysis of in vitro resistance to antimalarial drugs through nonlinear regression”. Computer Methods and Programs in Biomedicine 1 (2011): 10-18.
  20. Kaddouri H., et al. “Assessment of the drug susceptibility of Plasmodium falciparum clinical isolates from africa by using a Plasmodium lactate dehydrogenase immunodetection assay and an inhibitory maximum effect model for precise measurement of the 50-percent inhibitory concentration”. Antimicrobial Agents and Chemotherapy 10 (2006): 3343-3349.
  21. Woodring JV., et al. “Evaluation of recurrent parasitemia after artemether-lumefantrine treatment for uncomplicated malaria in children in western Kenya”. The American Journal of Tropical Medicine and Hygiene 3 (2010): 458-464.
  22. Clark TD., et al. “Incidence of malaria and efficacy of combination antimalarial therapies over 4 years in an urban cohort of Ugandan children”. PLoS One7 (2010): e11759.
  23. Pekyi D., et al. “Four Artemisinin-Based Treatments in African Pregnant Women with Malaria”. The New England Journal of Medicine 10 (2016): 913-927.
  24. Sirima SB., et al. “Comparison of artesunate-mefloquine and artemether-lumefantrine fixed-dose combinations for treatment of uncomplicated Plasmodium falciparum malaria in children younger than 5 years in sub-Saharan Africa: a randomised, multicentre, phase 4 trial”. The Lancet Infectious Diseases 10 (2016): 1123-1133.
  25. Phong NC., et al. “Susceptibility of Plasmodium falciparum to artemisinins and Plasmodium vivax to chloroquine in Phuoc Chien Commune, Ninh Thuan Province, south-central Vietnam”. Malaria Journal 1 (2019): 10.
  26. Kaddouri H., et al. “Baseline In vitro efficacy of ACT component drugs on Plasmodium falciparum clinical isolates from Mali”. International Journal for Parasitology 7 (2008): 791-798.
  27. Tinto H., et al. “Ex vivo anti-malarial drugs sensitivity profile of Plasmodium falciparum field isolates from Burkina Faso five years after the national policy change”. Malaria Journal 13 (2014): 207.
  28. Fall B., et al. “Ex vivo susceptibility of Plasmodium falciparum isolates from Dakar, Senegal, to seven standard anti-malarial drugs”. Malaria Journal 10 (2011): 310.
  29. Basco LK and P Ringwald. “Molecular epidemiology of malaria in Cameroon. XXIV. Trends of in vitro antimalarial drug responses in Yaounde, Cameroon”. The American Journal of Tropical Medicine and Hygiene 1 (2007): 20-26.
  30. Pascual A., et al. “Ex vivo activity of the ACT new components pyronaridine and piperaquine in comparison with conventional ACT drugs against isolates of Plasmodium falciparum”. Malaria Journal 11 (2012): 45.
Citation: Karim Traoré., et al. “Reduced Ex Vivo Sensitivity of Post Artemether-Lumefantrine Treatment Recurrent P. falciparum Isolates to Dihydroartemisinin and Piperaquine”. EC Pharmacology and Toxicology 9.4 (2021): 01-08.

PubMed Indexed Article


EC Pharmacology and Toxicology
LC-UV-MS and MS/MS Characterize Glutathione Reactivity with Different Isomers (2,2' and 2,4' vs. 4,4') of Methylene Diphenyl-Diisocyanate.

PMID: 31143884 [PubMed]

PMCID: PMC6536005


EC Pharmacology and Toxicology
Alzheimer's Pathogenesis, Metal-Mediated Redox Stress, and Potential Nanotheranostics.

PMID: 31565701 [PubMed]

PMCID: PMC6764777


EC Neurology
Differences in Rate of Cognitive Decline and Caregiver Burden between Alzheimer's Disease and Vascular Dementia: a Retrospective Study.

PMID: 27747317 [PubMed]

PMCID: PMC5065347


EC Pharmacology and Toxicology
Will Blockchain Technology Transform Healthcare and Biomedical Sciences?

PMID: 31460519 [PubMed]

PMCID: PMC6711478


EC Pharmacology and Toxicology
Is it a Prime Time for AI-powered Virtual Drug Screening?

PMID: 30215059 [PubMed]

PMCID: PMC6133253


EC Psychology and Psychiatry
Analysis of Evidence for the Combination of Pro-dopamine Regulator (KB220PAM) and Naltrexone to Prevent Opioid Use Disorder Relapse.

PMID: 30417173 [PubMed]

PMCID: PMC6226033


EC Anaesthesia
Arrest Under Anesthesia - What was the Culprit? A Case Report.

PMID: 30264037 [PubMed]

PMCID: PMC6155992


EC Orthopaedics
Distraction Implantation. A New Technique in Total Joint Arthroplasty and Direct Skeletal Attachment.

PMID: 30198026 [PubMed]

PMCID: PMC6124505


EC Pulmonology and Respiratory Medicine
Prevalence and factors associated with self-reported chronic obstructive pulmonary disease among adults aged 40-79: the National Health and Nutrition Examination Survey (NHANES) 2007-2012.

PMID: 30294723 [PubMed]

PMCID: PMC6169793


EC Dental Science
Important Dental Fiber-Reinforced Composite Molding Compound Breakthroughs

PMID: 29285526 [PubMed]

PMCID: PMC5743211


EC Microbiology
Prevalence of Intestinal Parasites Among HIV Infected and HIV Uninfected Patients Treated at the 1o De Maio Health Centre in Maputo, Mozambique

PMID: 29911204 [PubMed]

PMCID: PMC5999047


EC Microbiology
Macrophages and the Viral Dissemination Super Highway

PMID: 26949751 [PubMed]

PMCID: PMC4774560


EC Microbiology
The Microbiome, Antibiotics, and Health of the Pediatric Population.

PMID: 27390782 [PubMed]

PMCID: PMC4933318


EC Microbiology
Reactive Oxygen Species in HIV Infection

PMID: 28580453 [PubMed]

PMCID: PMC5450819


EC Microbiology
A Review of the CD4 T Cell Contribution to Lung Infection, Inflammation and Repair with a Focus on Wheeze and Asthma in the Pediatric Population

PMID: 26280024 [PubMed]

PMCID: PMC4533840


EC Neurology
Identifying Key Symptoms Differentiating Myalgic Encephalomyelitis and Chronic Fatigue Syndrome from Multiple Sclerosis

PMID: 28066845 [PubMed]

PMCID: PMC5214344


EC Pharmacology and Toxicology
Paradigm Shift is the Normal State of Pharmacology

PMID: 28936490 [PubMed]

PMCID: PMC5604476


EC Neurology
Examining those Meeting IOM Criteria Versus IOM Plus Fibromyalgia

PMID: 28713879 [PubMed]

PMCID: PMC5510658


EC Neurology
Unilateral Frontosphenoid Craniosynostosis: Case Report and a Review of the Literature

PMID: 28133641 [PubMed]

PMCID: PMC5267489


EC Ophthalmology
OCT-Angiography for Non-Invasive Monitoring of Neuronal and Vascular Structure in Mouse Retina: Implication for Characterization of Retinal Neurovascular Coupling

PMID: 29333536 [PubMed]

PMCID: PMC5766278


EC Neurology
Longer Duration of Downslope Treadmill Walking Induces Depression of H-Reflexes Measured during Standing and Walking.

PMID: 31032493 [PubMed]

PMCID: PMC6483108


EC Microbiology
Onchocerciasis in Mozambique: An Unknown Condition for Health Professionals.

PMID: 30957099 [PubMed]

PMCID: PMC6448571


EC Nutrition
Food Insecurity among Households with and without Podoconiosis in East and West Gojjam, Ethiopia.

PMID: 30101228 [PubMed]

PMCID: PMC6086333


EC Ophthalmology
REVIEW. +2 to +3 D. Reading Glasses to Prevent Myopia.

PMID: 31080964 [PubMed]

PMCID: PMC6508883


EC Gynaecology
Biomechanical Mapping of the Female Pelvic Floor: Uterine Prolapse Versus Normal Conditions.

PMID: 31093608 [PubMed]

PMCID: PMC6513001


EC Dental Science
Fiber-Reinforced Composites: A Breakthrough in Practical Clinical Applications with Advanced Wear Resistance for Dental Materials.

PMID: 31552397 [PubMed]

PMCID: PMC6758937


EC Microbiology
Neurocysticercosis in Child Bearing Women: An Overlooked Condition in Mozambique and a Potentially Missed Diagnosis in Women Presenting with Eclampsia.

PMID: 31681909 [PubMed]

PMCID: PMC6824723


EC Microbiology
Molecular Detection of Leptospira spp. in Rodents Trapped in the Mozambique Island City, Nampula Province, Mozambique.

PMID: 31681910 [PubMed]

PMCID: PMC6824726


EC Neurology
Endoplasmic Reticulum-Mitochondrial Cross-Talk in Neurodegenerative and Eye Diseases.

PMID: 31528859 [PubMed]

PMCID: PMC6746603


EC Psychology and Psychiatry
Can Chronic Consumption of Caffeine by Increasing D2/D3 Receptors Offer Benefit to Carriers of the DRD2 A1 Allele in Cocaine Abuse?

PMID: 31276119 [PubMed]

PMCID: PMC6604646


EC Anaesthesia
Real Time Locating Systems and sustainability of Perioperative Efficiency of Anesthesiologists.

PMID: 31406965 [PubMed]

PMCID: PMC6690616


EC Pharmacology and Toxicology
A Pilot STEM Curriculum Designed to Teach High School Students Concepts in Biochemical Engineering and Pharmacology.

PMID: 31517314 [PubMed]

PMCID: PMC6741290


EC Pharmacology and Toxicology
Toxic Mechanisms Underlying Motor Activity Changes Induced by a Mixture of Lead, Arsenic and Manganese.

PMID: 31633124 [PubMed]

PMCID: PMC6800226


EC Neurology
Research Volunteers' Attitudes Toward Chronic Fatigue Syndrome and Myalgic Encephalomyelitis.

PMID: 29662969 [PubMed]

PMCID: PMC5898812


EC Pharmacology and Toxicology
Hyperbaric Oxygen Therapy for Alzheimer's Disease.

PMID: 30215058 [PubMed]

PMCID: PMC6133268


News and Events


April Issue Release

We always feel pleasure to share our updates with you all. Here, notifying you that we have successfully released the April issue of respective journals and the latest articles can be viewed on the current issue pages.

Submission Deadline for upcoming Issue

Ecronicon delightfully welcomes all the authors around the globe for effective collaboration with an article submission for the upcoming issue of respective journals. Submissions are accepted on/before May 04, 2021.

Certificate of Publication

Ecronicon honors with a "Publication Certificate" to the corresponding author by including the names of co-authors as a token of appreciation for publishing the work with our respective journals.

Best Article of the Issue

Editors of respective journals will always be very much interested in electing one Best Article after each issue release. The authors of the selected article will be honored with a "Best Article of the Issue" certificate.

Certifying for Review

Ecronicon certifies the Editors for their first review done towards the assigned article of the respective journals.

Latest Articles

The latest articles will be updated immediately on the articles in press page of the respective journals.

Immediate Assistance

The prime motto of this team is to clarify all the queries without any delay or hesitation to avoid the inconvenience. For immediate assistance on your queries please don't hesitate to drop an email to editor@ecronicon.uk